Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Feb 1;97(3):852–857. doi: 10.1172/JCI118486

DCC protein expression in hematopoietic cell populations and its relation to leukemogenesis.

K Inokuchi 1, K Miyake 1, H Takahashi 1, K Dan 1, T Nomura 1
PMCID: PMC507125  PMID: 8609244

Abstract

Using flow cytometry and immunoprecipitation (IP), we have investigated the deleted in colon cancer (DCC) protein expression on the bone marrow (BM) and peripheral blood (PB) cells of 16 normal subjects, 17 myelodysplastic syndrome (MDS) patients, and 10 acute myelogenous leukemia (AML) patients. With regard to the BM mononuclear cells (BM-MNCs) of normal subjects, the DCC protein expression ranged from 6.6 to 57.0%. Two-color flow cytometry revealed that among the IBM-MNCs the DCC protein was clearly expressed on the CD14+, CD13+, and factor 8+ cells, whereas it was low on the CD19+ and CD7+ cells and did not express on the CD34+, CD8+, and the glycophorin A+ cells. Further, the DCC protein expression was not seen on the PB CD11b+ and CD13+ cells. The IP results revealed that the 180-kD DCC protein was detected on the MNCs of both the BM and PB cells by the antibodies AF5, specific for the DCC extracellular domain, and G97-449, specific for the cytoplasmic domain. In contrast, flow cytometry did not detect the DCC protein on any BM-MNC MDS lineages (0.1-1.5%) or on AML leukemic cells (0.1-0.9%). The IP results indicated that the AF5 antibody did not detect the DCC protein on BM-MNCs of three of five MDS patients and four of five AML patients; however, the G97-449 antibody detected the 180-kD DCC protein in two MDS patients in whom AF5 had detected greatly reduced DCC band. These findings suggest that the DCC protein presence appears to be associated with normal hematopoiesis, and that its absence on the surfaces of the BM-MNCs and AML cells may contribute to the MDS and AML pathogenesis.

Full Text

The Full Text of this article is available as a PDF (264.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abo J., Inokuchi K., Dan K., Nomura T. p53 and N-ras mutations in two new leukemia cell lines established from a patient with multilineage CD7-positive acute leukemia. Blood. 1993 Nov 1;82(9):2829–2836. [PubMed] [Google Scholar]
  2. Chenevix-Trench G., Leary J., Kerr J., Michel J., Kefford R., Hurst T., Parsons P. G., Friedlander M., Khoo S. K. Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus. Oncogene. 1992 Jun;7(6):1059–1065. [PubMed] [Google Scholar]
  3. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  4. Fearon E. R., Cho K. R., Nigro J. M., Kern S. E., Simons J. W., Ruppert J. M., Hamilton S. R., Preisinger A. C., Thomas G., Kinzler K. W. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990 Jan 5;247(4938):49–56. doi: 10.1126/science.2294591. [DOI] [PubMed] [Google Scholar]
  5. Gao X., Honn K. V., Grignon D., Sakr W., Chen Y. Q. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res. 1993 Jun 15;53(12):2723–2727. [PubMed] [Google Scholar]
  6. Hatzfeld J., Li M. L., Brown E. L., Sookdeo H., Levesque J. P., O'Toole T., Gurney C., Clark S. C., Hatzfeld A. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides. J Exp Med. 1991 Oct 1;174(4):925–929. doi: 10.1084/jem.174.4.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hedrick L., Cho K. R., Fearon E. R., Wu T. C., Kinzler K. W., Vogelstein B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev. 1994 May 15;8(10):1174–1183. doi: 10.1101/gad.8.10.1174. [DOI] [PubMed] [Google Scholar]
  8. Höhne M. W., Halatsch M. E., Kahl G. F., Weinel R. J. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res. 1992 May 1;52(9):2616–2619. [PubMed] [Google Scholar]
  9. Inokuchi K., Inoue T., Tojo A., Futaki M., Miyake K., Yamada T., Tanabe Y., Ohki I., Dan K., Ozawa K. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood. 1991 Dec 15;78(12):3125–3127. [PubMed] [Google Scholar]
  10. Klingelhutz A. J., Hedrick L., Cho K. R., McDougall J. K. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene. 1995 Apr 20;10(8):1581–1586. [PubMed] [Google Scholar]
  11. Lebkowski J. S., Schain L. R., Okrongly D., Levinsky R., Harvey M. J., Okarma T. B. Rapid isolation of human CD34 hematopoietic stem cells--purging of human tumor cells. Transplantation. 1992 May;53(5):1011–1019. doi: 10.1097/00007890-199205000-00009. [DOI] [PubMed] [Google Scholar]
  12. Miyake K., Inokuchi K., Dan K., Nomura T. Alterations in the deleted in colorectal carcinoma gene in human primary leukemia. Blood. 1993 Aug 1;82(3):927–930. [PubMed] [Google Scholar]
  13. Miyake K., Inokuchi K., Dan K., Nomura T. Expression of the DCC gene in myelodysplastic syndromes and overt leukemia. Leuk Res. 1993 Sep;17(9):785–788. doi: 10.1016/0145-2126(93)90113-y. [DOI] [PubMed] [Google Scholar]
  14. Miyake K., Inokuchi K., Nomura T. Expression of the DCC gene in human hematological malignancies. Leuk Lymphoma. 1994 Dec;16(1-2):13–18. doi: 10.3109/10428199409114135. [DOI] [PubMed] [Google Scholar]
  15. Miyake S., Nagai K., Yoshino K., Oto M., Endo M., Yuasa Y. Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res. 1994 Jun 1;54(11):3007–3010. [PubMed] [Google Scholar]
  16. Pierceall W. E., Cho K. R., Getzenberg R. H., Reale M. A., Hedrick L., Vogelstein B., Fearon E. R. NIH3T3 cells expressing the deleted in colorectal cancer tumor suppressor gene product stimulate neurite outgrowth in rat PC12 pheochromocytoma cells. J Cell Biol. 1994 Mar;124(6):1017–1027. doi: 10.1083/jcb.124.6.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Porfiri E., Secker-Walker L. M., Hoffbrand A. V., Hancock J. F. DCC tumor suppressor gene is inactivated in hematologic malignancies showing monosomy 18. Blood. 1993 May 15;81(10):2696–2701. [PubMed] [Google Scholar]
  18. Reale M. A., Hu G., Zafar A. I., Getzenberg R. H., Levine S. M., Fearon E. R. Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues. Cancer Res. 1994 Aug 15;54(16):4493–4501. [PubMed] [Google Scholar]
  19. Scheck A. C., Coons S. W. Expression of the tumor suppressor gene DCC in human gliomas. Cancer Res. 1993 Dec 1;53(23):5605–5609. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES